Dermatology
| Psoriasis
Dermatology
Psoriasis
Efficacy and safety of vunakizumab in moderate-to-severe psoriasis across different BMI classifications
book_2
Source:
EADV 2024 - Oral session
calendar_today
Published on Medfyle:
October 2024
import_contacts
4
min
In this medfyle
Psoriasis is associated with overweight or obesity, and this can impact the efficacy of some biologic therapies. New data on an investigational IL-17Ai explore efficacy and safety across BMI categories.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
©2024 Infomedica-Medfyle. All rights reserved.
Source: Efficacy and safety of vunakizumab in moderate-to-severe psoriasis across different BMI classifications. Li L, et al. Presented at EADV 2024; FC05.01; Abstract #3686.
The information and data provided is for information purposes only. The author(s) of the original original presentation had no involvement in the creation of this content.
